

3050 Spruce Street
Saint Louis, Missouri 63103 USA
Telephone 800-325-5832 • (314) 771-5765
Fax (314) 286-7828
email: techserv@sial.com
sigma-aldrich.com

ProductInformation

Ala-Tyr-Pro-Gly-Lys-Phe-NH₂ trifluoroacetate salt Product Number A 3227 Storage Temperature –20°C

Cas #: 352017-71-1

Synonyms: AYPGKF-NH₂, PAR4-AP

Product Description

Molecular Formula: C₃₄H₄₈N₈O₇ Molecular Weight: 680.8

Ala-Tyr-Pro-Gly-Lys-Phe-NH₂ (AYPGKF-NH₂) is a selective proteinase-activated receptor 4 (PAR4) specific agonist peptide, which may be used for probing PAR4 signaling in culture systems and in platelets.¹ AYPGKF stimulates platelet aggregation *in vitro* (EC₅₀ = 15 μM).² Human platelets with the PAR4 agonist AYPGKF stimulates the production of thromboxane.³ The thrombin-induced release of endostatin from rat platelets is mediated by the PAR4 agonist AYPGKF and in contrast, the PAR4 antagonist trans-cinnamoyl-YPGKF-NH₂ (Product No. C 7363) blocks endostatin release and platelet aggregation.⁴

Reagent

Ala-Tyr-Pro-Gly-Lys-Phe-NH $_2$ is supplied as a solid. Purity: \geq 98% (HPLC)

Precautions and Disclaimer

For R & D use only. Not for drug, household or other uses.

Consult the MSDS for information regarding hazards and safe handling practices.

Preparation Instructions

Ala-Tyr-Pro-Gly-Lys-Phe-NH₂ is soluble in water.

Storage/Stability

Store at -20 °C.

References

- Faruqi TR, et al., Structure-function analysis of protease-activated receptor 4 tethered ligand peptides. Determinants of specificity and utility in assays of receptor function. J. Biol. Chem., 275, 19728-19734 (2000).
- Hollenberg, M.D., and Saifeddine, M., Proteinaseactivated receptor 4 (PAR4): activation and inhibition of rat platelet aggregation by PAR4derived peptides. Can. J. Physiol. Pharmacol., 79, 439-442 (2001).
- 3. Henriksen, R.A., and Hanks, V.K., PAR-4 agonist AYPGKF stimulates thromboxane production by human platelets. Arterioscler. Thromb. Vasc. Biol., **22**, 861-866 (2002).
- 4. Ma, L., et al., Thrombin-induced platelet endostatin release is blocked by a proteinase-activated receptor 4 (PAR4) antagonist. Br. J. Pharmacol., **134**, 701-704 (2001).

KAA 04/03